The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2023 | Determinants of disease recurrence in non-metastatic, resected CRC
Julien Taieb, MD, PhD, Paris Descartes University, Paris, France, provides an overview of findings from an analysis of the prognostic value of KRAS and BRAF mutations in microsatellite-stable (MSS) and microsatellite instability-high (MSI-High) stage III colorectal cancer (CRC). The study, which molecularly profiled 8000 patients, revealed KRAS and BRAF mutations to be linked with increased recurrence. MSS colorectal cancer was additionally linked to higher rates of recurrence. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
